Vascular Stenting — Cost, Top Hospitals & Success Rates | MyMedicPlus

Vascular stenting places a metallic mesh tube (stent) inside a diseased blood vessel to restore and maintain luminal patency after balloon angioplasty (percutaneous transluminal angioplasty, PTA) or as a primary treatment for vessel dissection, elastic recoil, or flow-limiting stenosis. The procedure is performed percutaneously — most commonly via femoral, radial, or brachial arterial access — using fluoroscopic guidance and contrast angiography. A guide wire is advanced across the lesion, followed by a balloon catheter for pre-dilation, then stent deployment. Stent types include: bare metal stents (BMS), drug-eluting stents (DES — sirolimus or paclitaxel-coated to suppress neointimal hyperplasia and reduce restenosis), covered stents (stent-grafts for aneurysm exclusion, rupture, or fistula), self-expanding stents (nitinol — conformable to tortuous vessels such as the superficial femoral artery), and balloon-expandable stents (stainless steel or cobalt-chromium — high radial force for precise deployment in renal or iliac ostial lesions). Drug-coated balloons (DCBs) are increasingly used alongside or instead of permanent stent implants for femoropopliteal disease, delivering paclitaxel locally while avoiding a permanent implant. Carotid artery stenting (CAS), renal artery stenting, iliac artery stenting, superficial femoral artery (SFA) stenting, and intracranial stenting each require specific device selection and technique expertise.

Vascular stenting is applied across a broad range of arterial territories. Iliac artery disease: stenting is first-line treatment for aortoiliac occlusive disease (TASC A/B lesions) causing claudication or critical limb-threatening ischemia (CLTI), with primary stenting superior to PTA alone (DUTCH ILIAC study: 5-year patency 71% stent vs 57% PTA). Superficial femoral artery (SFA) disease: stenting for femoropopliteal stenosis/occlusion causing claudication or CLTI — TASC A/B preferred; drug-eluting stents and DCBs preferred over bare metal for 15–20 cm lesions. Carotid artery stenosis: CAS is the endovascular alternative to carotid endarterectomy (CEA) for high surgical risk patients with symptomatic stenosis ≥50% or asymptomatic stenosis ≥60–70%. Renal artery stenosis: stenting for atherosclerotic ostial renal artery stenosis causing renovascular hypertension or ischemic nephropathy refractory to optimal medical therapy. Subclavian artery stenosis: causing arm claudication, vertebrobasilar insufficiency, or coronary-subclavian steal in patients with prior CABG using internal mammary artery. Superior mesenteric artery (SMA) stenosis: chronic mesenteric ischemia causing postprandial pain and weight loss. Pulmonary artery stenosis: congenital or post-surgical narrowing. Intracranial atherosclerosis: selected patients with symptomatic severe stenosis refractory to dual antiplatelet therapy.

Patient selection depends on arterial territory, lesion characteristics, and clinical presentation. Iliac stenting: TASC A/B lesions are primary indications (primary stenting); TASC C/D may be treated endovascularly in experienced centers but open surgery remains preferred for durable long-segment occlusions. SFA stenting: TASC A/B lesions in claudicants or CLTI patients; lesion length ideally <15 cm for bare metal stents; DCBs extend feasibility to longer segments. CAS eligibility: carotid stenosis ≥50% (symptomatic) or ≥60% (asymptomatic) in patients at high surgical risk (prior neck dissection or radiation, contralateral carotid occlusion, severe cardiac or pulmonary comorbidity, restenosis after CEA, age >80 is a relative contraindication for CAS due to increased stroke risk from arch and carotid plaque). Dual antiplatelet therapy (aspirin 100 mg + clopidogrel 75 mg) must be initiated at least 3–5 days before peripheral stenting and continued for 1–3 months post-procedure (minimum); lifelong aspirin thereafter. Pre-procedure workup: duplex ultrasound, CTA or MRA for lesion characterization, ABI (ankle-brachial index), creatinine (contrast risk), cardiac evaluation for intermediate-to-high risk patients. Contraindications: uncorrectable coagulopathy, severe contrast allergy (pre-medication protocol or CO2 angiography), active systemic infection, lesion anatomy unsuitable for endovascular access.

Stent selection is based on vessel anatomy, location, disease pattern, and length of lesion. Balloon-expandable stents — typically stainless steel or chromium-cobalt alloys (Palmaz, Express LD, Herculink) — are deployed by balloon inflation and are preferred for the aorta, iliac, renal, mesenteric, and coronary arteries where radial force and precise deployment are critical. They resist external compression in rigid, calcified vessel environments. Self-expanding nitinol stents (Smart, Absolute Pro, Zilver PTX) are preferred for the femoropopliteal segment where repetitive flexion and external compression occur during ambulation — nitinol has a shape-memory property allowing the stent to expand to its pre-formed diameter upon release without balloon inflation. Drug-eluting stents (DES) — Zilver PTX (paclitaxel-coated nitinol, the only approved peripheral DES) — reduce in-stent restenosis by inhibiting neointimal hyperplasia; 2-year patency of 66% versus 43% for bare metal stent in femoropopliteal disease (ZILVER-PTX trial). Covered stents (stent-grafts) using PTFE or Dacron fabric lining prevent tissue ingrowth and are used for aortic aneurysm exclusion (EVAR), peripheral arterial injury repair, pseudoaneurysm exclusion, aortocaval/arteriovenous fistula closure, and for TIPS (transjugular intrahepatic portosystemic shunt) creation for portal hypertension. Intracranial stenting uses dedicated flexible self-expanding or balloon-expandable stents (Wingspan, Enterprise) for symptomatic intracranial stenosis refractory to medical therapy. Coronary artery stenting (PCI) uses drug-eluting stents (everolimus-eluting, zotarolimus-eluting) with bioresorbable polymer or polymer-free platforms.

Vascular stenting offers significant clinical benefits with a minimally invasive approach compared to open surgical bypass. Iliac stenting: 5-year primary patency 70–80% for TASC A/B lesions (comparable to surgical bypass for isolated aortoiliac disease, with substantially lower perioperative morbidity). SFA drug-eluting stent (ZILVER PTX trial): 12-month primary patency 83.1% vs 67.6% for PTA/BMS; 5-year data show sustained benefit. Drug-coated balloon (IN.PACT Admiral, ILLUMENATE trials): 12-month primary patency 79–82% with no permanent implant, 24-month data remain durable. CAS vs CEA (SAPPHIRE trial for high surgical risk): CAS non-inferior for 30-day major adverse events (4.8% CAS vs 9.8% CEA); CREST trial: CAS and CEA equivalent for long-term stroke or death prevention. Renal artery stenting: technical success >95%; blood pressure improvement in 50–70% of patients; renal function stabilization in patients with ischemic nephropathy. Same-day discharge possible for many peripheral stenting procedures. Significant improvement in walking distance (Rutherford claudication improvement) and quality of life at 12 months for SFA and iliac stenting.

Vascular stenting carries both procedure-related and stent-specific risks that vary by arterial territory. Access site complications are the most common: hematoma (2–5%), pseudoaneurysm (1–2%), arteriovenous fistula (<1%), retroperitoneal hemorrhage (femoral access, rare), and radial artery occlusion (5–10% with transradial access, usually asymptomatic). In-stent restenosis (ISR) is the primary long-term limitation, particularly in the SFA where repetitive flexion causes stent fatigue: BMS 12-month primary patency 60–65% (40–50% patency at 2 years); DES/DCB reduce ISR to 15–20% at 12 months. Stent fracture occurs in the SFA due to repetitive bending forces: 1–5% complete fractures with BMS, lower with flexible nitinol DES. Acute or subacute stent thrombosis requires dual antiplatelet therapy compliance — incidence <2% in peripheral territories with adequate antiplatelet therapy. Distal embolization (athero-embolism/trash foot): 1–3% during manipulation of heavily calcified lesions; embolic protection devices used during CAS reduce stroke risk. CAS-specific: periprocedural stroke 2–5% (higher in symptomatic patients and those with complex arch anatomy); higher than CEA in standard surgical risk patients (CREST, ICSS trials). Contrast-induced nephropathy: 2–5% in CKD patients — CO2 angiography, hydration, and dose minimization are protective.

Post-stenting surveillance targets in-stent restenosis (ISR), stent fracture, and late thrombosis. Peripheral arterial stents are monitored with colour duplex ultrasound at 1 month, 6 months, and annually, with ABI to document haemodynamic patency. Velocity criteria: peak systolic velocity ratio above 2.0–2.5 within the stented segment indicates significant ISR (greater than 50%) requiring reintervention — typically repeat angioplasty with drug-coated balloon or atherectomy. CT angiography provides superior anatomical detail for ISR assessment and is used when duplex is technically limited (obesity, calcification, bowel gas). Renal artery stenting surveillance: serum creatinine and eGFR at 1 month and 3 months to confirm renal function preservation; duplex renal artery ultrasound at 6 months and annually to assess stent patency and detect restenosis. Blood pressure monitoring assesses haemodynamic response to renal artery revascularisation. Antiplatelet therapy after peripheral arterial stenting: aspirin 100 mg daily indefinitely; dual antiplatelet (aspirin plus clopidogrel) for 1–6 months depending on stent type, vessel, and local protocol. After carotid artery stenting, dual antiplatelet therapy is maintained for minimum 30 days, then single antiplatelet indefinitely. Annual clinical review and risk factor modification (statin, blood pressure, diabetes, smoking cessation) are essential to reduce cardiovascular events and restenosis risk.

Vascular stenting costs vary by arterial territory, stent type, and healthcare system. Iliac artery stenting: India $3,000–8,000 (stent + procedure); USA $10,000–25,000; UK £6,000–16,000 (private; NHS for symptomatic disease); Thailand $5,000–12,000; Turkey $3,500–9,000; Germany €10,000–22,000. SFA stenting (DES/DCB): India $4,000–10,000; USA $12,000–30,000; Thailand $6,000–14,000; Turkey $4,000–10,000; Singapore $10,000–22,000. Carotid artery stenting (CAS): India $6,000–14,000; USA $20,000–50,000; UK £8,000–20,000 (private); Germany €15,000–30,000; Thailand $10,000–22,000. Renal artery stenting: India $3,500–9,000; USA $15,000–30,000; Australia $12,000–25,000. Device cost alone ranges $500–3,000 for bare metal stents, $2,000–6,000 for DES, and $3,000–7,000 for covered stent-grafts. Medical tourism to India, Thailand, or Turkey for peripheral vascular stenting offers savings of 60–75% compared to US prices, with comparable outcomes at JCI-accredited centers. Annual follow-up (duplex surveillance) adds $200–800 per year.

Balloon angioplasty alone (PTA without stenting) remains appropriate for short-segment lesions in vessels where primary stenting offers no additional benefit — particularly in tibial (infrapopliteal) arteries where small-calibre vessels and long lengths of disease make stenting less practical and angioplasty alone achieves acceptable wound healing. Drug-coated balloons (DCB) deliver paclitaxel to the vessel wall without leaving a permanent implant, reducing restenosis with 12-month patency comparable to DES in femoropopliteal disease. Atherectomy devices — directional (SilverHawk, TurboHawk), rotational (Jetstream, CSI Orbital), and laser (Spectranetics) — debulk atheromatous plaque before angioplasty or stenting, potentially reducing stent requirement and ISR risk. Open surgical bypass with autologous vein offers superior long-term durability for complex femoropopliteal and infrapopliteal disease in patients with adequate life expectancy and suitable conduit (BEST-CLI data). Endarterectomy is appropriate for localised common femoral artery, iliac, and visceral artery lesions. Optimal medical therapy — statins, antiplatelet agents, exercise rehabilitation — is the appropriate primary management for stable claudication, reserving revascularisation for CLTI or functional failure of conservative management. Hybrid procedures combining focal endarterectomy with distal bypass or stenting address complex multilevel disease.